TY - JOUR
T1 - De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock
T2 - Insights from the Critical Care Cardiology Trials Network Registry
AU - Bhatt, Ankeet S.
AU - Berg, David D.
AU - Bohula, Erin A.
AU - Alviar, Carlos L.
AU - Baird-Zars, Vivian M.
AU - Barnett, Christopher F.
AU - Burke, James A.
AU - Carnicelli, Anthony P.
AU - Chaudhry, Sunit Preet
AU - Daniels, Lori B.
AU - Fang, James C.
AU - Fordyce, Christopher B.
AU - Gerber, Daniel A.
AU - Guo, Jianping
AU - Jentzer, Jacob C.
AU - Katz, Jason N.
AU - Keller, Norma
AU - Kontos, Michael C.
AU - Lawler, Patrick R.
AU - Menon, Venu
AU - Metkus, Thomas S.
AU - Nativi-Nicolau, Jose
AU - Phreaner, Nicholas
AU - Roswell, Robert O.
AU - Sinha, Shashank S.
AU - Jeffrey Snell, R.
AU - Solomon, Michael A.
AU - Van Diepen, Sean
AU - Morrow, David A.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Heart failure-related cardiogenic shock (HF-CS) accounts for an increasing proportion of cases of CS in contemporary cardiac intensive care units. Whether the chronicity of HF identifies distinct clinical profiles of HF-CS is unknown. Methods and Results: We evaluated admissions to cardiac intensive care units for HF-CS in 28 centers using data from the Critical Care Cardiology Trials Network registry (2017–2020). HF-CS was defined as CS due to ventricular failure in the absence of acute myocardial infarction and was classified as de novo vs acute-on-chronic based on the absence or presence of a prior diagnosis of HF, respectively. Clinical features, resource use, and outcomes were compared among groups. Of 1405 admissions with HF-CS, 370 had de novo HF-CS (26.3%), and 1035 had acute-on-chronic HF-CS (73.7%). Patients with de novo HF-CS had a lower prevalence of hypertension, diabetes, coronary artery disease, atrial fibrillation, and chronic kidney disease (all P < 0.01). Median Sequential Organ Failure Assessment (SOFA) scores were higher in those with de novo HF-CS (8; 25th–75th: 5–11) vs acute-on-chronic HF-CS (6; 25th–75th: 4–9, P < 0.01), as was the proportion of Society of Cardiovascular Angiography and Intervention (SCAI) shock stage E (46.1% vs 26.1%, P < 0.01). After adjustment for clinical covariates and preceding cardiac arrest, the risk of in-hospital mortality was higher in patients with de novo HF-CS than in those with acute-on-chronic HF-CS (adjusted hazard ratio 1.36, 95% confidence interval 1.05–1.75, P = 0.02). Conclusions: Despite having fewer comorbidities, patients with de novo HF-CS had more severe shock presentations and worse in-hospital outcomes. Whether HF disease chronicity is associated with time-dependent compensatory adaptations, unique pathobiological features and responses to treatment in patients presenting with HF-CS warrants further investigation.
AB - Background: Heart failure-related cardiogenic shock (HF-CS) accounts for an increasing proportion of cases of CS in contemporary cardiac intensive care units. Whether the chronicity of HF identifies distinct clinical profiles of HF-CS is unknown. Methods and Results: We evaluated admissions to cardiac intensive care units for HF-CS in 28 centers using data from the Critical Care Cardiology Trials Network registry (2017–2020). HF-CS was defined as CS due to ventricular failure in the absence of acute myocardial infarction and was classified as de novo vs acute-on-chronic based on the absence or presence of a prior diagnosis of HF, respectively. Clinical features, resource use, and outcomes were compared among groups. Of 1405 admissions with HF-CS, 370 had de novo HF-CS (26.3%), and 1035 had acute-on-chronic HF-CS (73.7%). Patients with de novo HF-CS had a lower prevalence of hypertension, diabetes, coronary artery disease, atrial fibrillation, and chronic kidney disease (all P < 0.01). Median Sequential Organ Failure Assessment (SOFA) scores were higher in those with de novo HF-CS (8; 25th–75th: 5–11) vs acute-on-chronic HF-CS (6; 25th–75th: 4–9, P < 0.01), as was the proportion of Society of Cardiovascular Angiography and Intervention (SCAI) shock stage E (46.1% vs 26.1%, P < 0.01). After adjustment for clinical covariates and preceding cardiac arrest, the risk of in-hospital mortality was higher in patients with de novo HF-CS than in those with acute-on-chronic HF-CS (adjusted hazard ratio 1.36, 95% confidence interval 1.05–1.75, P = 0.02). Conclusions: Despite having fewer comorbidities, patients with de novo HF-CS had more severe shock presentations and worse in-hospital outcomes. Whether HF disease chronicity is associated with time-dependent compensatory adaptations, unique pathobiological features and responses to treatment in patients presenting with HF-CS warrants further investigation.
KW - cardiogenic shock
KW - critical care cardiology
KW - heart failure
UR - http://www.scopus.com/inward/record.url?scp=85116536167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116536167&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2021.08.014
DO - 10.1016/j.cardfail.2021.08.014
M3 - Article
C2 - 34625127
AN - SCOPUS:85116536167
SN - 1071-9164
VL - 27
SP - 1073
EP - 1081
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 10
ER -